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Purpose or Objective: The aim of this study was to compare 
treatment related side-effects and quality of life of an MRI-
based 95Gy boost to the multi-parametric MRI visible tumor 
with 77Gy whole prostate external beam radiotherapy in 
patients with intermediate or high risk localized prostate 
cancer. 
 
Material and Methods: FLAME (NCT01168479) was a phase 3, 
single blind, multi-center randomized controlled trial. 
Patients with biopsy proven intermediate and high risk 
prostate cancer (D’Amico risk classification) were randomly 
assigned and stratified per center. Analysis was done by 
intention to treat. The control group received a dose to the 
entire prostate of 77Gy in 35 fractions. The experimental arm 
received an additional integrated boost up to 95 Gy to the 
mp-MRI-visible lesions. Treatment related toxicity was 
measured by the Common Toxicity Criteria for adverse events 
version 3.0 (CTCAE). Quality of Life (QoL) was measured by 
SF-36, EORTC QLQ-C30 and EORTC QLQ-PR25. All items and 
scale scores were linearly transformed to a 0–100 scale, with 
higher scores reflecting either more symptoms or higher 
levels of functioning. Clinical relevance was considered a 
difference of more than 10 points between arms. Mean 
differences between groups were calculated using a linear 
mixed model with adjustment for baseline values. Statistical 
significance was considered P<0.01. 
 
Results: Between 2009 and 2015 287 patients were assigned 
to the control group and 284 to the dose-escalated (FLAME) 
arm. Mean follow up was 22 months. In both arms, 84% of 
patients had high risk disease. Regarding GU toxicity, 134 
patients (47.2%) in the FLAME arm and 147 patients (51.4%) in 
de control arm experienced any grade 2 or higher toxicity. 
Grade 3 GU toxicity occurred in 15 patients (5.3%) in the 
FLAME arm and 12 patients (4.2%) in the control arm. 
Regarding GI toxicity, 60 patients (21.1%) in the FLAME arm 
and 47 patients (16.4%) in the control arm experienced grade 
2 or higher toxicity. Grade 3 toxicity occurred in 2 patients 
(0.7%) in the FLAME arm and in 5 patients (1.7%) in the 
control arm. None of these differences were statistically 
significant. For all quality of life measures no statistically 
significant or clinical relevant differences were observed. 
 
 
Conclusion: Up to a median follow-up of 22 months no 
differences in toxicity and quality of life were observed 
between the FLAME arm and the standard arm. Therefore, 
dose escalated 95Gy MRI-based lesion boost in prostate 
cancer external beam radiotherapy seems safe. 
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Purpose or Objective: 'Watch and Wait' policy for complete 
clinical responders (cCR) following CRT is gaining acceptance 
as this avoids extirpative surgery and a stoma. However, up 
to 30% required major surgery for recurrences and organ 
preservation achieved reduced to 40% for the whole group. 
We report our experience with dose escalation using Contact 
X-ray brachytherapy [Papillon] (CXB) boost which reduce 
recurrences and improve the chance of organ preservation. 
 
Material and Methods: We review 573 patients with rectal 
cancer treated at Clatterbridge Cancer centre from 2003 -
2012 and report on 200 patients treated radically to cure by 
non-surgical approach. There were 134(67%) males with 
median age 74 years (range 32-94). Histological diagnosis 
confirmed in all patients. Staging include CT in all and MRI 
except in 30(15%) with pace maker. Radiological stages were 
21(10.5%) T1, 89(44.5%) T2, 87(43.5%) T3 and 3(1.5%) T4. 
EBCRT with 45 Gy /25#/35 days and capecitabine 825 mg/m 2 
or 5 FU infusion 1G /m 2 X 4 days week 1+5 was given to 127 
(63%)patients, except EBRT alone in unfit 57(28%) who had 25 
Gy/5#/5 days. Papillon boost of 80-110 Gy in 3-4 fraction was 
given to 92% of patients who had EBCRT or EBRT. Papillon 
alone (80-110 Gy /3-4 #/ 6 weeks) was used in 16 (8%) of 
elderly patients with mainly cT1 cancers. 
 
Results: Initial complete clinical response [cCR] (no residual 
tumor visible, palpable or on radiology) was achieved in 
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136(68%) and residual abnormality either clinical or 
radiological were seen in 64(32%). Immediate salvage surgery 
was carried out in 38(60%) patients with progressive residual 
disease who were fit. Eight (21%) had no pathological residual 
disease (ypT0). Surgery was withheld in further 8 (4%) out of 
64 without progression of residual abnormality. Those with 
cCR 116(85%) maintained complete response. Sixteen (11.7%) 
developed local relapse after cCR. Early staged tumors 
respond better with less local and total relapse. At median 
follow up of 2.49 months following completion of treatment; 
complete remission was achieved in 160 (80%) patients , 
12(6%) had asymptomatic static disease and 28 (14%) had 
progressive residual disease but not fit for salvage surgery 
due to age or medical co-morbidity. The main toxicity was 
bleeding occurring in 30% of cases and 10% needed argon 
beam. Organ preservation for the whole group was achieved 
in 158 (79%). Overall Survival (94% vs. 76%) [p=0.02] was 
better for responders (cCR +SD) at 2 years.  
 
Conclusion: CXB (Papillon) boost reduced local recurrence to 
11.7% after achieving cCR compared to 30-40% in those who 
had EBCRT alone. Organ preservation of 79% for the whole 
group is much higher than any ‘watch and wait’ studies with 
40% published so far. A randomised trial OPERA has been set 
up to evaluate this further. Papillon has acceptable toxicity 
and is now recommended by NICE for patients not suitable 
for surgery. Papillon should be consider as a treatment option 
for elderly patients with early rectal cancer. 
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Purpose or Objective: The programmed death ligand 1 (PD-
L1) plays a key role in tumour progression and metastasis of 
pancreatic ductal adenocarcinoma (PDAC). Although recent 
preclinical studies have explored the radiosensitising 
potential of PD-1/PD-L1 inhibitors, the effect of PD-L1 
blockade on the response of PDAC to radiotherapy remains 
unexplored. 
 
Material and Methods: Herein, we investigated the influence 
of an anti-PD-L1 mAb on the tumour response to single dose 
and fractionated radiotherapy, and chemotherapy with 
gemcitabine and capecitabine. 
 
Results: In-vitro, radiation and chemotherapy resulted in PD-
L1 upregulation in both human (PSN-1) and murine (KPC-
derived, Pan02) PDAC cells, although variability was 
observed. Exposure to conditioned media from pre-treated 
cells did not alter PD-L1 expression. In-vivo, PD-L1 was also 
upregulated in the tumour microenvironment after radiation 
and chemotherapy in the KPC-derived and Pan02 syngeneic 
mouse models. Similarly, chemotherapy induced PD-L1 
upregulation in the KPC (Pdx1Cre, KRASG12D/+, 
P53R172H/+), a genetically-engineered mouse model of 
pancreatic cancer. In-vitro, PD-L1 blockade failed to radio- or 
chemosensitise PDAC cells. The anti-PD-L1 mAb significantly 
improved tumour response after irradiation in the KPC and 
Pan02 syngeneic mouse models. This effect was mediated by 
a cytotoxic T cell-dependent mechanism, whereas blockade 
of CD8+ cells attenuated the radiosensitising potential of 
anti-PD-L1. The effect of scheduling of anti-PD-L1 mAb with 
radiotherapy (concomitant vs sequential) was also 
investigated. Finally, we assessed the intratumoural and 
systemic expression of several immune markers (CD45+: CD8, 
CD4, CD19, NK1.1, CD11b Gr1, Ly6G, CXCR2, FOXP3, IFN-γ) 
after the different treatments. 
 
Conclusion: Altogether, our findings support PD-L1 inhibition 
in combination with radiation as a promising approach in the 
treatment of PDAC. 
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Purpose or Objective: In this work, the design, fabrication, 
and operation of a small-scale graphite calorimeter probe 
(GPC) developed for use as a practical clinical dosimeter, is 
described. Similar in size and shape to a Farmer-type 
cylindrical ionization chamber, the GPC represents the first 
translation of calorimetry from the primary standards 
dosimetry laboratory to the radiotherapy clinic. Providing a 
measure of absolute dose, its purpose is to help meet the 
clinical need for accurate reference dosimetry in non-
standard fields without the need for calibration. 
 
 
 
Material and Methods: Based on a numerically-optimized 
design obtained in previous work, a functioning prototype 
capable of two independent modes of operation (constant-
power & constant-temperature) was constructed in-house. In 
constant-power mode, the radiation-induced temperature 
rise, ΔT, is measured in the sensitive volume (i.e. the core) 
while the outermost portion of the device is thermally 
stabilized by a software-based temperature controller. In 
constant-temperature mode, the entire device is subject to 
active thermal control and the quantity of interest is the 
electrical power, ΔP, necessary to maintain a stable 
temperature while irradiated. 
Absorbed dose to water measurements were performed in a 
water phantom, under standard conditions, using both GPC 
operation modes in a 6 MV photon beam and subsequently 
compared to dose to water measurements derived using a 
reference-class ionization chamber (Exradin A12). Linearity, 
dose rate, and field size dependence were evaluated by 
varying the irradiation period, the linac repetition rate, and 
primary collimating jaw settings, respectively. 
 
Results: Compared to the chamber-derived dose to water of 
0.765 cGy/MU, the average GPC-measured doses were 0.765 
± 0.005 (n = 25) and 0.769 ± 0.005 (n = 32) cGy/MU for the 
constant-power and constant-temperature modes, 
respectively. 
The linearity of the detector response was characterized by 
an adjusted R² value of 0.9996 (n = 40), and no 
statistically-significant dose rate dependence for rates 
greater than 1.8 Gy/min was observed. For lower dose rates, 
an over response of 1.7 % was attributed to the resolution of 
